Skip to main content

Table 1 Characteristics of included studies

From: Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials

Study (year) [Ref.]

Country

Patients

Inclusion criteria

Intervention: dose (mg/d)

Number randomized (withdrawals or dropouts)

Follow-up (months)

Grand I (2002) [26]

USA

HF-PEF and HBP

LVEF >50%; BP >140/90 mmHg; LV diastolic dysfunction; normal renal function

Canrenone:50

17 (NR)

6

ACEI

17 (NR)

Mottram (2004) [27]

Australia

HF-PEF and HBP

LVEF >50%; NYHA II; E/A <1

Spironolactone:25

15 (NR)

6

Placebo

15 (NR)

Roongsritong (2005) [28]

USA

Elderly with HF-PEF

LVEF >45%; Age:60–85 years; mild diastolic dysfunction

Spironolactone:25

15 (1)

4

Placebo

15 (1)

Orea-Tejeda (2007) [29]

Mexico

HF-PEF

LVEF >40%; shortening fraction = 28%

Spironolactone:25–50

14 (NR)

13.79

Standard therapy

14 (NR)

Mak (2009) [30]

Ireland

HF-PEF

LVEF >45%; NYHA IV; BNP ≥100 pg/mL; diastolic dysfunction

Eplerenone:25

24 (0)

12

Standard therapy

20 (2)

RAAM-PEF trial (2011) [31]

USA

HF-PEF

LVEF >50%; NYHA II or III; BNP ≥100 pg/mL

Eplerenone:25 (titrated to 50)

23 (0)

7

Placebo

23 (2)

Aldo-DHF trial (2013) [16]

Germany and Austria

HFPEF

LVEF >50%; NYHA II or III; Diastolic dysfunction grade ≥ I

Spironolactone:25

213 (9)

11.6

Placebo

209 (13)

Kurrelmeyer (2014) [32]

USA

Elderly women with HF-PEF

LVEF >50%; NYHA II or III; E/e' > 15; BNP >62 pg/mL

Spironolactone:25

24 (0)

6

Placebo

24 (0)

TOPCAT trial (2014) [14]

Americas, Russia, and Georgia

HF-PEF

LVEF >45%; control blood pressure; BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL, diastolic dysfunction (grade ≥ I)

Spironolactone:15–45

1722 (160)

39.6

Placebo

1723 (151)

DiPasquale (2005) [18]

Italy

MI-PEF

LVEF >40%; ST >1 mm in the peripheral leads and/or >2 mm in precordial leads

Canrenoate:25

341 (33)

6

placebo

346 (30)

Kayrak (2010) [19]

Turkey

MI-PEF

LVEF >40%; successfully revascularized patients with AMI

Spironolactone:25

71 (16)

6

Standard therapy

71 (16)

Kampourides (2012) [17]

Greece

MI-PEF

LVEF >40%; AMI 1 day to 7 days

Eplerenone:25

210 (9)

30

Standard therapy

140 (38)

Vatankulu (2013) [5]

Turkey

MI-PEF

LVEF >40%; successfully revascularized patients with AMI

Spironolactone:25

54 (NR)

6

Standard therapy

56 (NR)

REMINDER trial (2014) [15]

European countries

MI-PEF

LVEF >40%; successfully revascularized patients with AMI

Eplerenone: 25 (titrated to 50)

506 (82)

10.5

Placebo

506 (79)

  1. ACEI, Angiotensin-converting enzyme inhibitor; AMI, Myocardial infarction; BNP, B-type natriuretic peptide; E/A ratio, the ratio of early to late diastolic transmitral flow; E/e', an echocardiographic estimate of filling pressure for assessment of diastolic function; HBP, High blood pressure; HF-PEF, Heart failure with preserved systolic function; LVEF, Left ventricular ejection fraction; MI-PEF, Myocardial infarction with preserved systolic function; NR, Not reported; NT-proBNP, Amino terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association functional class.